CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Spero Therapeutics Appoints William Ho to Board and Development Committee

By Public Technologies
  • Spero Therapeutics appointed William Ho to its board and Development Committee effective November 10, 2026; he brings over 20 years’ clinical development experience.
  • Patrick Vink stepped down from the board concurrently, ending 11 years of service.
  • Debra Jeske Zack became chief medical officer in July 2026; she previously held that role at Exagen.
  • Amy Rock was recently appointed chief regulatory and quality officer to lead global regulatory strategy, quality and pharmacovigilance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876515) on November 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk